Keywords: topotarget, curagen, begin, dosing, blood, cancer, study

TopoTarget and CuraGen begin dosing in blood cancer study

Article | 14 August 2006

Print This

Denmark's TopoTarget AS and USA-based CuraGen say they have initiated patient dosing in a Phase I trial of PDX101, their ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in